标题
Proteasome inhibitors in cancer therapy
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 14, Issue 7, Pages 417-433
出版商
Springer Nature
发表日期
2017-01-24
DOI
10.1038/nrclinonc.2016.206
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- LBA28CARFILZOMIB (K) VS LOW-DOSE CORTICOSTEROIDS AND OPTIONAL CYCLOPHOSPHAMIDE (CY) IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 3 STUDY (FOCUS)
- (2017) H. Ludwig et al. ANNALS OF ONCOLOGY
- Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1
- (2016) P. G. Richardson et al. BLOOD
- Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling
- (2016) Xing-Ding Zhang et al. CANCER CELL
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial
- (2015) Vaishali Sanchorawala et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
- (2015) J. J. Shah et al. BLOOD
- Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma
- (2015) P. Moreau et al. BLOOD
- Inflammation rapidly reorganizes mouse bone marrow B cells and their environment in conjunction with early IgM responses
- (2015) J. M. Moreau et al. BLOOD
- A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
- (2015) G. Palladini et al. BLOOD
- Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
- (2015) Ronan T. Swords et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601
- (2015) Brian G. Till et al. BRITISH JOURNAL OF HAEMATOLOGY
- The role of heat shock proteins in cancer
- (2015) Georgios D. Lianos et al. CANCER LETTERS
- Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
- (2015) M. Andreeff et al. CLINICAL CANCER RESEARCH
- Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
- (2015) J. J. Shah et al. CLINICAL CANCER RESEARCH
- The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma
- (2015) Bingzong Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
- (2015) Tadeusz Robak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells
- (2015) Hiroaki Kimura et al. Journal of Immunology Research
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
- (2014) N. Lendvai et al. BLOOD
- Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia
- (2014) S. P. Treon et al. BLOOD
- The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
- (2014) A. Spencer et al. BLOOD
- Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
- (2014) P. G. Richardson et al. BLOOD
- Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring
- (2014) Ajai Chari et al. BMC CANCER
- Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials
- (2014) Zebo Huang et al. Future Oncology
- Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
- (2014) D. Dytfeld et al. HAEMATOLOGICA
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
- (2014) Shaji K Kumar et al. LANCET ONCOLOGY
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
- (2013) M. A. Dimopoulos et al. BLOOD
- A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma
- (2013) Maria T. Petrucci et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
- (2013) Chungyee Leung-Hagesteijn et al. CANCER CELL
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials
- (2013) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma
- (2013) Elisabet E. Manasanch et al. LEUKEMIA & LYMPHOMA
- Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
- (2013) Eyal C. Attar et al. LEUKEMIA RESEARCH
- Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
- (2013) H. A. F. Stessman et al. MOLECULAR CANCER THERAPEUTICS
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
- (2012) J. R. Mikhael et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
- (2012) W. Blum et al. BLOOD
- Sequence analysis of -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone
- (2012) D. I. Lichter et al. BLOOD
- Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
- (2012) Y. H. Messinger et al. BLOOD
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
- (2012) L. Rosinol et al. BLOOD
- Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
- (2012) J. B. Egan et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
- (2012) D. J. Kuhn et al. BLOOD
- Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
- (2012) Roman Hájek et al. BMC CANCER
- A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
- (2012) M. Alsina et al. CLINICAL CANCER RESEARCH
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502
- (2012) Eyal C. Attar et al. JOURNAL OF CLINICAL ONCOLOGY
- Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma
- (2012) Yadan Wang et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors
- (2012) Simone Cenci et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma
- (2011) M. A. Weniger et al. CLINICAL CANCER RESEARCH
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
- (2011) B. C. Potts et al. CURRENT CANCER DRUG TARGETS
- Proteasome inhibitor treatment of antibody-mediated allograft rejection
- (2011) E. Steve Woodle et al. Current Opinion in Organ Transplantation
- Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis
- (2011) A. M. Gomez et al. JOURNAL OF IMMUNOLOGY
- Myeloperoxidase-Specific Plasma Cell Depletion by Bortezomib Protects from Anti-Neutrophil Cytoplasmic Autoantibodies-Induced Glomerulonephritis
- (2011) J. Bontscho et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Bortezomib: Understanding the Mechanism of Action
- (2011) B. Piperdi et al. MOLECULAR CANCER THERAPEUTICS
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Long-lived autoreactive plasma cells drive persistent autoimmune inflammation
- (2011) Falk Hiepe et al. Nature Reviews Rheumatology
- Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
- (2010) Irene M. Ghobrial et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
- (2010) P. Perez-Galan et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1and p57Kip2CDK inhibitors
- (2010) Zhimin Lu et al. CELL CYCLE
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
- (2010) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
- (2009) John Gerecitano et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
- (2009) O. A. O'Connor et al. CLINICAL CANCER RESEARCH
- Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line
- (2009) Shuqing Lü et al. EXPERIMENTAL HEMATOLOGY
- Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
- (2009) Steven P. Treon et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells
- (2009) T Rückrich et al. LEUKEMIA
- Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology
- (2008) Alan L. Schwartz et al. Annual Review of Pharmacology and Toxicology
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- Proteasome Subunit Pharmacogenomics: Gene Resequencing and Functional Genomics
- (2008) L. Wang et al. CLINICAL CANCER RESEARCH
- Thymoproteasome: probable role in generating positively selecting peptides
- (2008) Shigeo Murata et al. CURRENT OPINION IN IMMUNOLOGY
- Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
- (2008) Asher Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Point Mutation of the Proteasome 5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line
- (2008) S. Lu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
- (2008) Kirsten Neubert et al. NATURE MEDICINE
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now